All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @aaron.endres on TikTok · 71s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @aaron.endres's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Stop messing up.
  2. 0:00You're spending money on this.
  3. 0:01Let me show you how to have a constitute redder.
  4. 0:03Backwater, redder.
  5. 0:05I'm just gonna use your insulin syringe
  6. 0:06because it's what I have.
  7. 0:07Pop off both tops and you're going to alcohol swab each one.
  8. 0:10We are going to be using a 100 unit insulin syringe
  9. 0:13for the backwater.
  10. 0:13I want you to pull out 100 units.
  11. 0:16Just make sure no air bubbles.
  12. 0:17Grab your bottle of redder.
  13. 0:18We are doing a five milligram here.
  14. 0:20I want you to put this in at a slight angle
  15. 0:22to where the backwater will run down the side
  16. 0:25of the peptide.
  17. 0:27A lot of times it'll just naturally pull in by itself,
  18. 0:30but just don't shoot it abruptly directly
  19. 0:32into the powder itself,
  20. 0:33but it dripped down the side of the vial.
  21. 0:35Once that is all in, just go ahead and grab the vial
  22. 0:38and you can just rotate it in your fingers.
  23. 0:40You guys can take it, roll around in your hands like this.
  24. 0:43Just make sure you are not shaking it
  25. 0:45and that powder will completely dissolve on its own.
  26. 0:48Now with this concentration, how do we dose it?
  27. 0:50When you actually pull back from the redder vial now,
  28. 0:53every 20 units is going to be one milligram of redder.
  29. 0:57One milligram is 22 milligrams will be 40 units.
  30. 1:00And then of course, you guys can titrate up or down
  31. 1:02depending to dose preferences.
  32. 1:03So where do you get it?
  33. 1:04Everything I get is from Nova Papsler.
  34. 1:05I trusted the third party company.
  35. 1:07We got to see it go online, see all of these sites there,
  36. 1:09but that is my trusted source as needed.

@aaron.endres's peptide reconstitution tips, fact-checked

Aaron Endres

TikTok creator

1.2M viewsWatch on TikTok

Quick answer

The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.S. The creator's concentration math (20 units per milligram from a 5mg vial in 1mL bac water) is arithmetically correct, but his verbal explanation is garbled in a way that creates real dosing confusion risk. Retatrutide's dose-dependent adverse event profile, including nausea, vomiting, and potential cardiovascular effects, makes unmonitored self-dosing based on a social media video a meaningful safety concern.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @aaron.endres's peptide reconstitution tips, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@aaron.endres's peptide reconstitution tips, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@aaron.endres's peptide reconstitution tips, fact-checked" from Aaron Endres. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.

The reason this review is not generic is the source wording and the canonical claim label "peptides how to reconstitute a so you don t mess it up nova peps." In this clip, the useful excerpt is: "Stop messing up." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Jastreboff et al.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video demonstrates reconstitution of what is almost certainly retatrutide (LY3437943), a triple receptor agonist in Phase 3 clinical trials that is not FDA-approved or legally available as a compounded prescription in the U.S. The creator's concentration math (20 units per milligram from a 5mg vial in 1mL bac water) is arithmetically correct, but his verbal explanation is garbled in a way that creates real dosing confusion risk. Retatrutide's dose-dependent adverse event profile, including nausea, vomiting, and potential cardiovascular effects, makes unmonitored self-dosing based on a social media video a meaningful safety concern.
  • Retatrutide is not FDA-approved and is not legally available as a compounded prescription in the United States as of 2024.
  • Jastreboff et al. 2023 (NEJM) showed up to 24 percent body weight reduction with retatrutide in Phase 2, but all dosing was medically supervised with a slow titration protocol over many weeks.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Retatrutide is not FDA-approved and is not legally available as a compounded prescription in the United States as of 2024.
  • Jastreboff et al. 2023 (NEJM) showed up to 24 percent body weight reduction with retatrutide in Phase 2, but all dosing was medically supervised with a slow titration protocol over many weeks.
  • The reconstitution technique shown (bac water down the vial wall, gentle rotation, no shaking) is technically sound and consistent with standard peptide handling practice.
  • The creator's dose calculation contains a verbal error that could cause viewers to misidentify their concentration, and a dosing mistake with a GLP-1/GIP/glucagon agonist can cause serious GI or cardiovascular adverse events.
  • Unregulated peptide vendors are not subject to FDA Current Good Manufacturing Practice rules, meaning purity, sterility, and labeled concentration are unverified claims.
  • Phase 2 adverse events for retatrutide included nausea in up to 60 percent of participants at higher doses, plus vomiting, diarrhea, and tachycardia, none of which were mentioned in this video.
  • FDA-approved GLP-1 receptor agonists prescribed through a regulated medical provider represent a legal, clinically monitored alternative for people interested in this drug class for weight management.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @aaron.endres actually say?

Aaron walked through how to reconstitute what he calls "redder" — a thinly veiled reference to retatrutide — using bacteriostatic water and an insulin syringe. His core instructions: pull 100 units of bac water into a 100-unit insulin syringe, inject it slowly down the side of the vial, rotate gently rather than shaking, and then calculate doses as 20 units per milligram from a 5mg vial. He also plugged Nova Peptides as his sourcing choice, calling them his "trusted source."

The video has 1.2 million views. That reach matters here, because retatrutide is not approved by the FDA, is not legally available by prescription in the United States, and the people watching this are almost certainly self-administering a research compound without medical supervision.

Does the science back this up?

The reconstitution technique itself is largely sound. The math, however, has a significant error that could lead to serious dosing mistakes. Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist that showed meaningful weight loss in Phase 2 trials, but it is still in clinical development.

The Jastreboff et al. 2023 study published in the New England Journal of Medicine tested retatrutide doses between 1mg and 12mg weekly in people with obesity. The drug produced dose-dependent weight loss but also dose-dependent GI side effects including nausea, vomiting, and diarrhea. In that trial, doses were titrated slowly by trained clinicians over many weeks. There is no published data on the safety profile of self-administered compounded retatrutide outside of controlled clinical settings, and that gap is not a small one.

What did they get wrong (or right)?

Credit where it is due: injecting bac water down the side of the vial rather than directly into the powder is standard reconstitution practice and reduces the chance of protein degradation. Gentle rotation over shaking is also correct. Alcohol swabbing both stoppers is basic sterile technique that many amateur reconstitution videos skip entirely.

Here is what he got wrong, and it matters. He says "one milligram is 22 milligrams will be 40 units." That sentence is incoherent, but if you follow his logic: 100 units of bac water into a 5mg vial means each milligram equals 20 units. That math actually checks out for 20 units per milligram. But then he says "2 milligrams will be 40 units" in a garbled way that could easily be misread. Anyone who miscalculates concentration here is not off by 10 percent, they could be injecting a multiple of their intended dose. At retatrutide's potency range, that is a meaningful clinical risk.

His sourcing plug for "Nova Papsler" (Nova Peptides) is unverified by any independent third-party analysis presented in this video. He says he "trusted the third party company" and vaguely references seeing lab results online. That is not the same as independently verified certificate of analysis data.

What should you actually know?

Retatrutide is not FDA-approved. It is not legally dispensed as a prescription compound in the United States. Purchasing it from peptide vendors means you are buying an unregulated research chemical with no guaranteed purity, sterility, or concentration accuracy. The Phase 2 data from Jastreboff et al. is genuinely compelling — up to 24 percent body weight reduction at 48 weeks in some dose groups — but that trial used pharmaceutical-grade drug with medical oversight and a slow titration schedule.

Self-injection of a GIP/GLP-1/glucagon agonist without baseline labs, without cardiovascular screening, and without a titration protocol is not the same thing as participating in a clinical trial. Pancreatitis, tachycardia, and severe GI events were among the adverse effects noted in the Phase 2 data. None of that is mentioned in a 60-second reconstitution TikTok reaching 1.2 million people.

If you are interested in GLP-1 class therapy for weight management, a regulated telehealth provider can evaluate whether FDA-approved options like semaglutide or tirzepatide are appropriate for your situation, with actual medical oversight.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Aaron Endres · TikTok creator

1.2M views on this video

How to reconstitute 🐀-a so you don’t mess it up! Nova peps code ACE

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about retatrutide?

Retatrutide is not FDA-approved and is not legally available as a compounded prescription in the United States as of 2024.

What does the video say about jastreboff et al. 2023 (nejm) showed up to 24 percent?

Jastreboff et al. 2023 (NEJM) showed up to 24 percent body weight reduction with retatrutide in Phase 2, but all dosing was medically supervised with a slow titration protocol over many weeks.

What does the video say about the reconstitution technique shown (bac water down the vial wall,?

The reconstitution technique shown (bac water down the vial wall, gentle rotation, no shaking) is technically sound and consistent with standard peptide handling practice.

What does the video say about the creator's dose calculation contains a verbal error?

The creator's dose calculation contains a verbal error that could cause viewers to misidentify their concentration, and a dosing mistake with a GLP-1/GIP/glucagon agonist can cause serious GI or cardiovascular adverse events.

What does the video say about unregulated peptide vendors?

Unregulated peptide vendors are not subject to FDA Current Good Manufacturing Practice rules, meaning purity, sterility, and labeled concentration are unverified claims.

What does the video say about phase 2 adverse events for retatrutide included nausea in up?

Phase 2 adverse events for retatrutide included nausea in up to 60 percent of participants at higher doses, plus vomiting, diarrhea, and tachycardia, none of which were mentioned in this video.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Aaron Endres, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.